Literature DB >> 30218634

The vascular morphology of melanoma is related to Breslow index: An in vivo study with dynamic optical coherence tomography.

Nathalie De Carvalho1, Julia Welzel2, Sandra Schuh2, Lotte Themstrup3,4, Martina Ulrich5, Gregor B E Jemec3,4, Jon Holmes6, Shaniko Kaleci1, Johanna Chester1, Laura Bigi1, Silvana Ciardo1, Giovanni Pellacani1.   

Abstract

BACKGROUND: Malignant melanoma is an aggressive skin cancer, which can lead to metastasis development. Vascularization enhancement is fundamental for tumor growth, worsening the prognosis. Dynamic optical coherence tomography (D-OCT) enables the in vivo evaluation of vascular patterns in skin lesions.
OBJECTIVE: In vivo evaluation of the melanoma vessel morphology by means of D-OCT and correlation with Breslow index.
METHODS: Retrospective analysis of histologically proven melanomas, evaluated by D-OCT at three different depths (150, 300 and 500 μm), was performed. Vessels were classified according to morphology (dots, blobs, coiled, line, curved, serpiginous), distribution (regular, irregular) and the presence/type of branches. The data were correlated with Breslow thickness.
RESULTS: A total of 127 melanomas were evaluated. Dotted vessels were recorded at all depths, and their irregular distribution was associated with lesions thicker than 1.0 mm (from 75% to 91%), compared with thin ones (42%) at 150 μm (P = 0.031), and from 33% to 57% vs 18% at 300 μm (P = 0.021). Serpiginous and branching vessels with bulges were predominantly seen in melanomas thicker than 2 mm at 150 μm (from 14% to 27%, P < 0.001) and 300 μm of depth (from 36% to 54%, P < 0.001). LIMITATIONS: Background noise hampered vessel detection at 500 μm. No correlation with dermoscopy/histology.
CONCLUSION: Vascular pattern evaluation at 150 and 300 μm provided data on tumor microvascular asset and its pattern of progression in accordance with Breslow thickness. Since vascular progression is theoretically linked with tumor aggressiveness, the study of vascular pattern related with melanoma metastatization capability is warranted.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  dynamic OCT; melanoma; metastatization; neovascularization; tumor growth

Mesh:

Year:  2018        PMID: 30218634     DOI: 10.1111/exd.13783

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  5 in total

1.  Fast raster-scan optoacoustic mesoscopy enables assessment of human melanoma microvasculature in vivo.

Authors:  Hailong He; Christine Schönmann; Mathias Schwarz; Benedikt Hindelang; Andrei Berezhnoi; Susanne Annette Steimle-Grauer; Ulf Darsow; Juan Aguirre; Vasilis Ntziachristos
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

2.  Dermoscopic features in different dermatopathological stages of cutaneous melanomas.

Authors:  Katarzyna Podolec; Agnieszka Bronikowska; Magdalena Pirowska; Anna Wojas-Pelc
Journal:  Postepy Dermatol Alergol       Date:  2019-03-04       Impact factor: 1.837

3.  Multispectral Imaging Algorithm Predicts Breslow Thickness of Melanoma.

Authors:  Szabolcs Bozsányi; Noémi Nóra Varga; Klára Farkas; András Bánvölgyi; Kende Lőrincz; Ilze Lihacova; Alexey Lihachev; Emilija Vija Plorina; Áron Bartha; Antal Jobbágy; Enikő Kuroli; György Paragh; Péter Holló; Márta Medvecz; Norbert Kiss; Norbert M Wikonkál
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

4.  Nomogram Incorporating the WNT/β-Catenin Signaling Pathway for Predicting the Survival of Cutaneous Melanoma.

Authors:  Yu-Xin Zhou; Xin Wang; De-Quan Pang; Ying-Man Wang; Jing Bai; Fei Tian; Duo Han; Shuwei Shi; Lei Hu
Journal:  Int J Gen Med       Date:  2021-06-23

5.  Capillary Refill-The Key to Assessing Dermal Capillary Capacity and Pathology in Optical Coherence Tomography Angiography.

Authors:  M J Casper; J Glahn; M Evers; H Schulz-Hildebrandt; G Kositratna; R Birngruber; G Hüttmann; D Manstein
Journal:  Lasers Surg Med       Date:  2019-11-21       Impact factor: 4.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.